GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BUE:MRK) » Definitions » Cyclically Adjusted Revenue per Share

Merck (BUE:MRK) Cyclically Adjusted Revenue per Share : ARS4,458.46 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Merck Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck's adjusted revenue per share for the three months ended in Mar. 2024 was ARS52,242.287. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS4,458.46 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Merck's average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck was 17.80% per year. The lowest was -2.50% per year. And the median was 3.40% per year.

As of today (2024-06-04), Merck's current stock price is ARS32045.00. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS4,458.46. Merck's Cyclically Adjusted PS Ratio of today is 7.19.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.17. And the median was 4.35.


Merck Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Merck's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted Revenue per Share Chart

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 248.30 488.72 706.58 1,284.91 3,891.46

Merck Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,577.67 2,019.60 3,304.90 3,891.46 4,458.46

Competitive Comparison of Merck's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.



Merck Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=52242.287/131.7762*131.7762
=52,242.287

Current CPI (Mar. 2024) = 131.7762.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 301.250 100.560 394.767
201409 305.323 100.428 400.629
201412 310.574 99.070 413.106
201503 290.142 99.621 383.792
201506 311.970 100.684 408.310
201509 333.954 100.392 438.356
201512 469.839 99.792 620.424
201603 486.556 100.470 638.163
201606 493.426 101.688 639.424
201609 564.117 101.861 729.791
201612 577.831 101.863 747.520
201703 525.828 102.862 673.635
201706 594.934 103.349 758.576
201709 663.477 104.136 839.583
201712 729.737 104.011 924.536
201803 746.257 105.290 933.986
201806 968.090 106.317 1,199.916
201809 1,483.228 106.507 1,835.135
201812 1,574.334 105.998 1,957.206
201903 1,624.270 107.251 1,995.703
201906 2,030.236 108.070 2,475.599
201909 2,695.624 108.329 3,279.064
201912 969.131 108.420 1,177.903
202003 2,938.239 108.902 3,555.414
202006 2,524.867 108.767 3,058.984
202009 3,196.883 109.815 3,836.211
202012 3,506.290 109.897 4,204.359
202103 3,767.336 111.754 4,442.288
202106 4,252.407 114.631 4,888.417
202109 5,071.759 115.734 5,774.754
202112 5,386.532 117.630 6,034.343
202203 6,729.693 121.301 7,310.850
202206 6,913.290 125.017 7,287.077
202209 8,176.841 125.227 8,604.513
202212 9,099.684 125.222 9,575.983
202303 11,218.765 127.348 11,608.887
202306 14,211.894 128.729 14,548.344
202309 21,939.914 129.860 22,263.743
202312 20,784.849 129.419 21,163.353
202403 52,242.287 131.776 52,242.287

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Merck  (BUE:MRK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32045.00/4458.46
=7.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.17. And the median was 4.35.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (BUE:MRK) Business Description

Industry
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (BUE:MRK) Headlines

From GuruFocus

Q4 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Merck Announces Second-Quarter 2024 Dividend

By Business Wire 01-23-2024

Q1 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Investor Event at ACC.23/WCC Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at ASCO Annual Meeting Transcript

By GuruFocus Research 01-23-2024